What is Iantrek?
Founded by ophthalmic innovator Sean Ianchulev, MD, MPH, Iantrek is a venture-funded medical technology company dedicated to pioneering bio-interventional and micro-interventional products for ophthalmic surgery. The company's innovative portfolio includes solutions such as AlloSert Uveo, AlloFlo Uveo, CanaloFlo, and C.Rex, which are designed for the management of complex conditions including glaucoma. Iantrek's strategic focus on developing advanced surgical tools positions it as a key player in advancing the precision and efficacy of eye surgeries.
How much funding has Iantrek raised?
Iantrek has raised a total of $135M across 5 funding rounds:
Series A
$5.2M
Series B
$23M
Series C
$42M
Private Equity
$34.7M
Debt
$30M
Series A (2020): $5.2M, investors not publicly disclosed
Series B (2022): $23M led by Sectoral Asset Management and Visionary Ventures
Series C (2025): $42M supported by US Venture Partners, aMoon, Visionary Ventures, and Sectoral Asset Management
Private Equity (2025): $34.7M, investors not publicly disclosed
Debt (2026): $30M backed by Trinity Capital
Key Investors in Iantrek
Trinity Capital
Trinity Capital is a leading provider of debt financing, including loans and equipment financing, to growth-stage companies backed by venture capital and institutional equity investors, focusing on current income and capital appreciation through term loans and equipment financings.
US Venture Partners
U.S. Venture Partners (USVP) is a prominent Silicon Valley venture capital firm specializing in early-stage investments across cybersecurity, enterprise software, consumer products, and healthcare, leveraging its network to support transformative companies.
aMoon
aMoon is a healthcare investment firm that partners with scientists and entrepreneurs to build companies focused on transforming healthcare through technology and biology, investing in disruptive solutions for high unmet medical needs.
What's next for Iantrek?
With the recent influx of major strategic investment and substantial overall capital, Iantrek is poised for accelerated development and market expansion. This significant backing, particularly the enterprise-level funding, suggests a trajectory towards scaling operations, further research and development into its pipeline of ophthalmic solutions, and potentially broader commercialization efforts. The company's focus on interventional products for glaucoma and other eye conditions indicates a strategic push to address significant unmet needs within the ophthalmology market, aiming to enhance surgical outcomes and patient care.
See full Iantrek company page
